HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Core Viewpoint - Hoth Therapeutics' shares surged 178.2% following the announcement of positive interim safety and efficacy results from a mid-stage study of HT-001, aimed at treating skin toxicities in cancer patients undergoing EGFR inhibitor therapy [1] Group 1: Study Results - All patients in the phase IIa study achieved the primary efficacy endpoint of an ARIGA score ≤1, indicating significant improvement in skin toxicity by the six-week mark [2] - 66% of patients reported reduced pain and itching scores, enhancing their quality of life, while all patients maintained their full EGFR inhibitor dosage, avoiding treatment interruptions [3] - The interim results suggest HT-001 has the potential to become the new standard of care for severe skin toxicities associated with EGFR inhibitors, with no treatment-related adverse events reported [5] Group 2: Future Development Plans - Hoth plans to report more data as the phase IIa study progresses, further validating HT-001's therapeutic benefits for skin toxicities [8] - The company continues to enroll patients in the mid-stage study and has previously reported rapid resolution of EGFR inhibitor-induced skin conditions using HT-001 [6] Group 3: Development Pipeline - Beyond HT-001, Hoth's clinical pipeline includes BioLexa, an investigational candidate for atopic dermatitis, along with several pre-clinical candidates targeting various oncology, neurology, dermatology, and inflammatory indications [9]